ALK S1206Y

CI-VAR-00003989Explore in graph →NP_004295.2:p.Ser1206TyrNM_004304.4:c.3617C>AClinVar 376133 CIViC 172 rs1057519782

Curated evidence

Evidence by cancer (4 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–4 of 4 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma4
ALK S1206Y AND v::ALK Fusion	Ceritinib	Predictive	C	Supports Sensitivity Response	2	submitted	EID2865 In a prospective study (NCT01283516) of 130 cancer patients, a non-small cell lung cancer patient harboring a S1206Y mutation in the ALK portion of the ALK rearrangement was associated with a 60% resp… (full text at CIViC) PMID 24670165 · Shaw et al., 2014 · Open in CIViC	civic
EML4::ALK Fusion AND ALK S1206Y	Ceritinib	Predictive	D	Supports Sensitivity Response	2	accepted	EID1343 Ba/F3 cells expressing the EML4-ALK S1206Y variant were treated with ceritinib, and survival GI50 value of 1.5 nM was obtained, which compares favorably with GI50 of 1.7 for the highly ceritinib sensi… (full text at CIViC) PMID 24675041 · Friboulet et al., 2014 · Open in CIViC

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.